In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Arrowhead Pharmaceuticals’ current price far exceeds its fair value of $32.59, indicating significant overvaluation with a -62.5% implied downside. Despite high liquidity and growth scores, profitability and efficiency are at zero, signaling risk in fundamental performance. Monte Carlo analysis shows no downside scenarios, but wide valuation method disparities highlight uncertainty.